FDA Grants Breakthrough Therapy Designation for Tucatinib in HER2-Positive Breast Cancer

Seattle Genetics announced the development after data was presented at the 2019 San Antonio Breast Cancer Symposium.

Source: CancerNetwork - December 19, 2019 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news